Flagship explainer
What drives NovoCure Limited’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$136M | FY2025 |
| |
| Income before tax | −$136M | FY2025 |
|
| Operating income | −$154M | FY2025 |
|
| $655M | FY2025 |
| |
| Ending assets | $804M | FY2025 |
|
| Beginning assets | $1.2B | FY2024 |
|
| $340M | FY2025 |
| |
| $360M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001645113-26-000017